Coherus BioSciences to Participate at Upcoming September Investor Conferences

Coherus BioSciences to Participate at Upcoming September Investor Conferences

September 01, 2023 | Last Trade: US$0.81 0.06 8.32

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

Citi's 2023 18th Annual BioPharma Conference in Boston on Wednesday, September 6, 2023, including participation in an I-O Panel Discussion at 3:30 p.m. EDT.
2023 Wells Fargo Healthcare Conference in Boston on Thursday, September 7, 2023 for 1x1 meetings only.
H.C. Wainwright 25^th Annual Global Investment Conference in New York on September 12-13, 2023 for a fireside chat-format presentation on Tuesday, September 12, 2023 at 1:30 pm EDT.

A live audio webcast and an archive of the presentations from the Citi and HCW conferences will be available on the investors’ page of the Coherus website at http://investors.coherus.com.

Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$0.81
Daily Change:	0.06 8.32
Daily Volume:	1,352,099
Market Cap:	US$94.140M

May 27, 2025 Coherus BioSciences Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) May 12, 2025 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update April 28, 2025 Coherus BioSciences Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 March 25, 2025 Coherus BioSciences to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting March 10, 2025 Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE